Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02458638 · ClinicalTrials.gov registry record · Phase 2
A Study of Atezolizumab in Advanced Solid Tumors
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 474
- Enrollment target
NCT02458638 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 474 participants.
The verdict
NCT02458638, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 474 participants
- Enrollment target
Study Summary
The primary efficacy objective for this study is to evaluate non-progression rate (NPR) at 18 weeks in participants with advanced solid tumors treated with atezolizumab, defined as the percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1, or according to disease-specific criteria for prostate cancer and malignant pleural mesothelioma.
Interventions
- DRUG Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 474 participants |
| Start Date | 2015-07-16 |
| Est. Completion | 2020-07-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02458638
The ClinicalTrials.gov registry entry for NCT02458638 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 474 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody is the first listed.
NCT02458638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02458638 about?
NCT02458638 is a clinical study titled "A Study of Atezolizumab in Advanced Solid Tumors". The primary efficacy objective for this study is to evaluate non-progression rate (NPR) at 18 weeks in participants with advanced solid tumors treated with atezolizumab, defined as the percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) as assessed b...
What is the current status of trial NCT02458638?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 474 participants. The study started on 2015-07-16. Estimated completion is 2020-07-28.
What interventions are being tested in trial NCT02458638?
The interventions under investigation include: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody (DRUG).
Who is sponsoring clinical trial NCT02458638?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.